Prime Medicine, Inc. (PRME) Announces Fourth Quarter Loss, Falls Short of Revenue Projections

Prime Medicine, Inc. (PRME) Reports Quarterly Results

Prime Medicine, Inc. (PRME) announced a quarterly net loss of $0.22 per share, which was better than the consensus estimate of a $0.25 loss. In comparison, the company reported a loss of $0.31 per share during the same period last year. These results exclude one-time items.

This quarter’s performance resulted in a positive earnings surprise of 13.39%. In the previous quarter, analysts had anticipated a loss of $0.28 per share, but the actual loss was $0.32, reflecting a negative surprise of 14.29%.

Over the past year, Prime Medicine has only exceeded consensus earnings per share estimates once out of the last four quarters.

Within the Medical - Biomedical and Genetics sector, Prime Medicine posted revenue of $0.84 million for the quarter ending December 2025, falling short of the consensus estimate by 63.64%. This is a decrease from $2.18 million in revenue reported a year earlier. The company has not surpassed revenue expectations in any of the last four quarters.

The direction of Prime Medicine’s stock price in the near term will likely be influenced by management’s comments during the earnings call, as well as future earnings projections.

Since the start of the year, Prime Medicine’s share price has climbed approximately 34.3%, compared to a 0.5% increase in the S&P 500 index.

What Lies Ahead for Prime Medicine, Inc.?

Although Prime Medicine has outperformed the broader market so far this year, investors are now considering what the future holds for the stock.

While there is no simple answer, one useful indicator for investors is the company’s earnings outlook, which includes not only current consensus forecasts for upcoming quarters but also recent changes in those estimates.

Studies have shown a strong link between short-term stock price movements and trends in earnings estimate revisions. Investors can monitor these changes themselves or use established rating systems such as the Zacks Rank, which has a strong history of leveraging earnings estimate trends.

Prior to this earnings announcement, revisions to Prime Medicine’s estimates were mixed. The latest results may influence future estimate changes, but for now, the stock holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market.

It will be important to watch how earnings and revenue estimates for the next quarters and the current fiscal year evolve. The current consensus projects an EPS of -$0.25 on $1.77 million in revenue for the next quarter, and an EPS of -$0.96 on $5.31 million in revenue for the fiscal year.

Investors should also consider the broader industry outlook, as it can significantly impact stock performance. The Medical - Biomedical and Genetics industry currently ranks in the bottom 45% of over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperform the bottom half by more than two to one.

Industry Comparison: Lineage Cell (LCTX)

Lineage Cell (LCTX), another company in the same sector, has not yet released its results for the quarter ending December 2025. These results are expected on March 5.

Analysts anticipate Lineage Cell will report a quarterly loss of $0.07 per share, which would represent a 600% decline compared to the same period last year. The consensus EPS estimate has remained unchanged over the past month.

Lineage Cell’s revenue is projected to be $2.3 million, a 20% decrease from the previous year’s quarter.

Is Prime Medicine, Inc. (PRME) a Good Investment?

Before deciding to invest in Prime Medicine, Inc. (PRME), you may want to explore the top stock picks for the next 30 days. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent analysis and tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500’s performance during the period from January 1, 1988, to May 6, 2024.

Looking for the latest stock recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days for free.